RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
🧠🙏 #Glioma: a small molecule inhibitor suppressed tumor growth in #mice 🐁 with #cancer with mutations on the H3F3A gene https://t.co/Tq9H97lvBd https://t.co/szzGMW4lka
أمل جديد لعلاج بعض الأورام الدبقية الطافرة بالجين H3F3A عند الأطفال، وذلك باستخدام المثبط WP1066 الذي يكبح نشاط السبيل الخلوي STAT3 https://t.co/V4VqtTmPx6
$MBRX #WP1066
Study identifies the LIF−STAT3 pathway as a key epigenetic driver of high-grade gliomas with arginine or valine substitutions of the histone H3.3 glycine-34 residue, which could be disrupted using the STAT3 inhibitor WP1066 in mouse models: https://t.co/Xw
RT @UMRogelCancer: 🔥🔥🔥 New research from @vennetilab on the cover of @ScienceTM! #btsm "When given to mice carrying H3.3G34R/V tumors, WP…
RT @OWLMSPA: @moleculinbio #WP1066 What a great news, research is the key. Congrats and GL in clinical trials. #dipg
🧠🙏 #Gliome: un inhibiteur à petite molécule capable de supprimer la croissance tumorale chez la #souris 🐁, dans le cas d'un #cancer à mutations du gène H3F3A https://t.co/Tq9H97lvBd https://t.co/jTcduvERSE
RT @epicancerpapers: Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas https://t.co/yEQpZgdcwM
RT @OWLMSPA: @moleculinbio #WP1066 What a great news, research is the key. Congrats and GL in clinical trials. #dipg
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
@moleculinbio #WP1066 What a great news, research is the key. Congrats and GL in clinical trials. #dipg
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas https://t.co/Bca5zFyZ1h
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas https://t.co/yEQpZgdcwM
RT @weldeiry: Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas https://t.co/4xYIIqZHAe
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
New in Pubmed: "Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas" https://t.co/PXcRSbK8vw
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas https://t.co/4xYIIqZHAe
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @vennetilab: Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also ma…
RT @UMRogelCancer: 🔥🔥🔥 New research from @vennetilab on the cover of @ScienceTM! #btsm "When given to mice carrying H3.3G34R/V tumors, WP…
🔥🔥🔥 New research from @vennetilab on the cover of @ScienceTM! #btsm "When given to mice carrying H3.3G34R/V tumors, WP1066 suppressed tumor growth, suggesting that inhibition of STAT3 signaling may be of therapeutic value in H3.3G34R/V gliomas." ➡️http
Very excited to share our new paper on therapies for H3G34R/V mutant high-grade gliomas. https://t.co/kDgTSp3J8J We also made the cover!! https://t.co/7lazVWX2MK